...
首页> 外文期刊>Journal of Surgical Oncology >Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer
【24h】

Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer

机译:壁外延伸作为IIA期(pT3N0)结肠癌术后辅助化疗的指标

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The usefulness of adjuvant chemotherapy (CMT) in patients with Stage IIA colon cancer remains unclear. The present study aimed to investigate extramural extension as an indicator for adjuvant CMT. Data were reviewed from 202 consecutive patients with Stage IIA colon cancer that underwent curative surgery between 1995 and 2007. The distance of the extramural extension (DEE) was measured histologically. The optimal prognostic cut-off point of the DEE for oncologic outcomes was statistically determined. The eligible surviving patients had been followed for a median period of 75 months (range: 2-210 months). Patients were subdivided into two groups according to the optimal cut-off point; DEE ≤5 mm (pT3a) and DEE >5 mm (pT3b). The pT3b was the most powerful independent risk factor for postoperative recurrence (P = 0.0324, HR: 3.04, 95% CI: 1.098-8.408), and was significantly correlated with distant metastasis (P = 0.0161 HR: 5.19, 95% CI: 1.765-15.239). The recurrence-free and cancer-specific 5-year survival rates in patients with pT3b were significantly lower than in patients with pT3a (81.5% vs. 95.4%, P = 0.0003 and 85.9% vs. 97.4%, P = 0.0007, respectively). pT3b could be an important risk factor for distant metastasis in Stage IIA colon cancer. Postoperative adjuvant CMT may be indicated for patients with pT3b. J. Surg. Oncol. 2013; 108:358-363.
机译:辅助化疗(CMT)在IIA期结肠癌患者中的用途尚不清楚。本研究旨在调查壁外延伸作为辅助CMT的指标。回顾性分析了1995年至2007年间202例接受根治性手术的IIA期结肠癌患者的数据。组织学测量了壁外延伸的距离(DEE)。统计确定DEE对肿瘤结局的最佳预后临界点。对合格的存活患者进行了75个月的中位随访(范围:2-210个月)。根据最佳分界点将患者分为两组。 DEE≤5毫米(pT3a)和DEE> 5毫米(pT3b)。 pT3b是术后复发的最有力的独立危险因素(P = 0.0324,HR:3.04,95%CI:1.098-8.408),并且与远处转移密切相关(P = 0.0161 HR:5.19,95%CI:1.765) -15.239)。 pT3b患者的无复发和癌症特异性5年生存率显着低于pT3a患者(分别为81.5%和95.4%,P = 0.0003和85.9%vs. 97.4%,P = 0.0007) 。 pT3b可能是IIA期结肠癌远处转移的重要危险因素。 pT3b患者可能需要术后辅助CMT。 J. Surg。 Oncol。 2013; 108:358-363。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号